---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-24-000024"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2024-02-15T23:59:59+00:00"
generated_at: "2026-06-06T01:11:59.387626+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nurix FY2023 revenue $77.0M, net loss $143.9M; NX-5948 Fast Track, NX-2127 partial hold

## Summary
- FY2023 revenue $77.0M (up from $38.6M), net loss $143.9M ($2.65/share) vs $180.4M ($3.71) prior year.
- Cash and investments $295.3M as of Nov 30, 2023, up from $268.7M at Aug 31, 2023.
- NX-5948 granted FDA Fast Track for CLL; positive Phase 1 data with durable responses.
- NX-2127 placed on partial clinical hold by FDA; expects to resolve in 2024.
- Generated $100M non-dilutive capital from partners in 2023; licensed IRAK-4 degrader NX-0479/GS-6791 to Gilead.

## SEC filing metadata
- accession: 0001549595-24-000024
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2024-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959524000024/0001549595-24-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959524000024/nrix-20240215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-24-000024
- JSON: https://secwatch.observer/filing/0001549595-24-000024.json
- Plain text: https://secwatch.observer/filing/0001549595-24-000024.txt

## Key facts
- Earnings Releases
  Nurix Therapeutics, Inc. reported financial results for the fiscal quarter and fiscal year ended November 30, 2023.
  - Period: the fiscal quarter and fiscal year ended November 30, 2023
  - Result: reported results
  source text: today reported financial results for the fiscal quarter and fiscal year ended November 30, 2023, and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549595/000154959524000024/0001549595-24-000024-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.